KALA BIO (KALA) Proxy Filing summary

Board of directors and corporate governance

• David Lazar's biography updated to reflect recent executive roles at Indaptus Therapeutics, Byrn, Inc., and Humitech International Group, Inc. as of December 2025 and July 2023, respectively.

• David Lazar has held multiple CEO, CFO, and board positions at various public companies from 2018 through 2025, highlighting extensive leadership and capital markets experience.

• Belief in Lazar's qualifications is based on his diverse knowledge of capital markets and experience leading public companies.

Voting matters and shareholder proposals

• Supplement serves as solicitation material for votes on matters described in the Proxy Statement for the 2025 Annual Meeting scheduled for January 30, 2026.

• Investors are urged to review the Proxy Statement and related materials for important information regarding the matters to be voted on.

Related party transactions

• Certain directors, executive officers, and employees may be considered participants in the solicitation of proxies for stockholder approvals.